Pharvaris N.V. (NASDAQ:PHVS) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Pharvaris N.V. (NASDAQ:PHVS) have earned a consensus rating of “Moderate Buy” from the fourteen research firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, ten have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $50.0833.

Several brokerages recently commented on PHVS. HC Wainwright reiterated a “buy” rating on shares of Pharvaris in a report on Tuesday, June 16th. Royal Bank Of Canada lowered their price target on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a report on Monday, April 6th. UBS Group set a $74.00 price target on shares of Pharvaris in a research report on Wednesday, May 13th. Wells Fargo & Company assumed coverage on shares of Pharvaris in a research note on Wednesday, July 15th. They issued an “overweight” rating and a $55.00 price objective on the stock. Finally, Wolfe Research began coverage on shares of Pharvaris in a research report on Thursday, April 9th. They set an “outperform” rating and a $42.00 price objective for the company.

Insider Buying and Selling at Pharvaris

In other Pharvaris news, Director Viviane Monges sold 9,667 shares of the company’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $30.29, for a total transaction of $292,813.43. Following the sale, the director owned 5,500 shares of the company’s stock, valued at approximately $166,595. This represents a 63.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Anna Nijdam sold 2,670 shares of Pharvaris stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $30.87, for a total value of $82,422.90. Following the completion of the transaction, the insider directly owned 46,275 shares of the company’s stock, valued at approximately $1,428,509.25. This trade represents a 5.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 303,356 shares of company stock valued at $9,746,065.

Hedge Funds Weigh In On Pharvaris

Institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC grew its position in shares of Pharvaris by 41.1% during the 2nd quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock worth $952,000 after buying an additional 15,769 shares during the period. JPMorgan Chase & Co. boosted its stake in Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares in the last quarter. Legal & General Group Plc boosted its stake in Pharvaris by 17.2% during the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after acquiring an additional 1,695 shares in the last quarter. Amundi grew its holdings in Pharvaris by 2,741,600.0% in the second quarter. Amundi now owns 27,417 shares of the company’s stock worth $489,000 after purchasing an additional 27,416 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in Pharvaris by 19.2% in the second quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock worth $860,000 after purchasing an additional 7,879 shares during the period.

Pharvaris Trading Down 4.0%

Shares of PHVS opened at $33.55 on Thursday. The stock’s 50-day moving average price is $32.23 and its two-hundred day moving average price is $29.06. Pharvaris has a 12 month low of $19.12 and a 12 month high of $36.60. The company has a market capitalization of $2.19 billion, a PE ratio of -10.55 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.12. Equities research analysts predict that Pharvaris will post -3.2 EPS for the current fiscal year.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.